Investor Presentaiton

sanofi At least 5 new FiC / BiC programs expected to enter phase 3 by 2025 2022-2023 progress Pipeline moving at pace 3 new products registered 6 new phase 1/2 programs Phase 3 & Registration mRNA Flu QIV Beyfortus ✓ RSV Older Adult ✓ RSV OA/PIV/hMPV 凡尔佳 Phase 1/2 ✓ MenPenta VaxigripTetra® 四价流感病毒裂解疫苗く Acne ✓ NextGen Flu VidPrevtyn™) COVID-19 vaccine (recombinant, adjuvanted) Beta 14 Vaccines Investor Event 2021 2023e 2025e Pre-clinical

View entire presentation